Clinical pharmacokinetics of an amorphous solid dispersion tablet of elacridar

Emilia Sawicki(Royal Women's Hospital), Neeltje Steeghs(Peter MacCallum Cancer Centre), Olaf van Tellingen(Dutch Cancer Society), Remy B. Verheijen(AstraZeneca (United Kingdom)), Jos H. Beijnen(The Netherlands Cancer Institute), Jan H.M. Schellens(Utrecht University), Bastiaan Nuijen(The Netherlands Cancer Institute), Alwin D. R. Huitema(The Netherlands Cancer Institute)
Drug Delivery and Translational Research
November 18, 2016
10.1007/s13346-016-0346-3
Cited by 16

Related Papers

Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs
|Cell|1994|2.3k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k
Overcoming the blood–brain tumor barrier for effective glioblastoma treatment
|Drug Resistance Updates|2015|1k
Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins
|Proceedings of the National Academy of Sciences|1997|941
Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine
|Proceedings of the National Academy of Sciences|1997|884